IGFBP-2

Your glucose and HbA1c can look normal while insulin resistance develops. Insulin resistance means your muscles, fat, and liver respond less effectively to insulin. Studies have linked lower circulating IGFBP-2 with this pattern, more liver fat, and a greater likelihood of developing prediabetes or type 2 diabetes.

Those associations make IGFBP-2 interesting for prevention research. Its usefulness for directing your care remains unproven. There are no standardized clinical decision limits for these uses, and studies haven't established that adding the test improves health outcomes. Higher levels also accompany several illnesses, so the number needs context.

What This Protein Does

IGFBP-2 binds insulin-like growth factors 1 and 2, usually called IGF-1 and IGF-2. These proteins help regulate growth and cell survival. Binding affects how long they circulate and how they interact with tissues. IGFBP-2 is produced in several tissues, including the liver and fat tissue, and can also affect cells independently of the growth factors it carries.

Its relationship with insulin is more complicated than direct suppression. People with insulin resistance often have lower baseline levels, but controlled insulin infusions have increased IGFBP-2 in human experiments. The association between a low level and insulin resistance doesn't establish that excess insulin is the sole cause.

Age also matters. Levels are relatively high in infancy, decline through childhood, and tend to rise again in later adulthood. Sex differences have varied between study populations. Small human studies found less day-to-day and meal-related fluctuation than for IGFBP-1, although prolonged fasting raised levels.

This test reports a blood concentration in ng/mL. The catalog doesn't specify whether the laboratory uses serum or plasma, or which measurement method it uses. Both sample types appear in the research below, and they are prepared differently. Findings about associations may be relevant, but numerical results from different sample types or assays cannot be assumed interchangeable.

Insulin Resistance and Type 2 Diabetes

The most consistent metabolic findings involve lower levels. A study using plasma samples compared 742 women who developed type 2 diabetes with 742 matched controls. Women in the highest fifth of IGFBP-2 had 83% lower odds of developing diabetes than those in the lowest fifth, after adjustment for other risk factors. This was an observational association, not evidence that raising the protein prevents diabetes.

A separate study measured serum IGFBP-2 in middle-aged adults whose glucose tolerance was initially normal. Many had a family history of diabetes. Women in the lowest quarter had about seven and a half times the odds of developing prediabetes over eight years compared with those in the highest quarter. The associations differed between women and men, which limits applying one estimate to everyone.

Pregnancy research found a similar direction. In a study comparing 107 gestational diabetes cases with 214 controls, the highest quarter of plasma IGFBP-2 at 10 to 14 weeks was associated with 96% lower odds of later gestational diabetes than the lowest quarter. That striking estimate came from a relatively small observational comparison. It doesn't establish a replacement for routine gestational diabetes screening.

Higher circulating levels were also associated with a lower likelihood of developing metabolic syndrome in a community cohort. Together, these studies support further investigation of IGFBP-2 as a metabolic risk marker. They don't establish an individual diagnostic rule or a treatment target.

Liver Fat and Blood Fats

In 333 apparently healthy adults, lower plasma IGFBP-2 was associated with more body fat, a less favorable blood-fat profile, and more liver fat. The liver-fat association remained after accounting for fat around the abdominal organs and sex. Related imaging research found that IGFBP-2 was associated with differences in liver fat even among people with excess abdominal organ fat.

These studies measured the protein and liver fat at the same time. They couldn't establish which changed first or whether either caused the other. Routine liver enzymes can remain unremarkable despite fatty liver, but that doesn't make IGFBP-2 a validated substitute for imaging or established liver assessment.

A study of 219 men examined plasma IGFBP-2 alongside the movement of fat-carrying particles through the blood. Lower levels were associated with higher triglycerides, slower removal of particles carrying fat from the liver, and faster production of particles carrying fat absorbed from food. These findings help explain the metabolic pattern associated with IGFBP-2 without proving that the protein controls those processes in people.

Heart Disease and Heart Failure

In several groups with established cardiovascular disease, higher IGFBP-2 was associated with worse outcomes. These studies examined prognosis after disease was already present. They do not establish its accuracy for finding heart disease in otherwise healthy adults.

In the heart-failure cohorts, IGFBP-2 added statistical prognostic information beyond standard natriuretic peptide measurements. That finding hasn't established that treatment decisions based on IGFBP-2 improve outcomes.

Researchers also studied serum IGFBP-2 in pulmonary arterial hypertension. This condition causes high blood pressure in the arteries supplying the lungs. In one cohort of 200 people, levels above the median were associated with about four times the death rate after adjustment, though the estimate was imprecise. The adjusted association was not statistically conclusive in the separate, smaller cohort.

Dementia and Alzheimer's Disease

Among 1,596 dementia-free participants in the Framingham Offspring Study, those in the highest third of plasma IGFBP-2 had about 2.9 times the rate of dementia during nearly 12 years of follow-up compared with the lowest third. The corresponding rate of Alzheimer's disease was about 3.6 times higher.

Adding IGFBP-2 improved some measures of risk classification within that cohort. The study didn't establish a clinically validated memory-screening test, and it didn't show that lowering IGFBP-2 protects cognition. A blood result also doesn't establish what the protein is doing inside your brain.

Aging and Death From Any Cause

Higher levels have predicted mortality in some older and chronically ill populations. In 1,417 adults with type 2 diabetes followed for about five years, each doubling of serum IGFBP-2 was associated with about 2.2 times the death rate after adjustment for other risk factors.

A 20-year study of 539 adults illustrates how much the interpretation depends on other characteristics. The relationship with mortality changed after researchers accounted for insulin sensitivity: higher levels were then associated with greater mortality. The study cannot establish why that happened in each person or turn an individual result into a lifespan estimate.

Why High and Low Have Different Associations

Circulating IGFBP-2 reflects several processes. Body fat and insulin sensitivity contribute, but so do age, nutritional status, kidney disease, severe illness, and some tumors. A higher value can occur alongside favorable metabolic measurements or alongside illness. The blood concentration alone cannot distinguish those explanations.

Kidney disease is especially relevant because elevated levels have been associated with impaired kidney function and active lupus nephritis. Both altered protein handling and changes in production may contribute. The evidence doesn't justify treating every increase as reduced kidney clearance or every decrease as recovery.

Cancer

Some tumors produce IGFBP-2, and studies have found higher blood levels in groups with lung, colorectal, ovarian, and prostate cancer. A meta-analysis covering 21 studies and 5,560 people with cancer linked higher IGFBP2 measurements with about a 57% higher death rate during follow-up. It combined blood measurements with tumor-tissue measurements, including different ways of assessing protein or gene activity. That pooled estimate cannot be applied directly to this blood test.

The single-marker detection results also show its limitations. One colorectal cancer study identified about 80% of cancers while incorrectly classifying 36% of healthy controls as positive. A pancreatic cancer study identified only 22% of cancers when the analysis was set to correctly classify 95% of people without cancer.

These were research comparisons involving people with known disease and selected controls. They don't establish effective screening in the general population. An isolated high IGFBP-2 result is not evidence that you have cancer.

When Results Can Be Misleading

• Kidney disease: reduced kidney function and active kidney inflammation can accompany higher levels, making a purely metabolic interpretation unreliable.
• Nutrition and illness: prolonged fasting, undernutrition, and severe illness can raise levels. An increase in these circumstances should not be interpreted as improved insulin sensitivity.
• Age and hormonal conditions: levels change with age and can be elevated in growth hormone deficiency. The relationship with growth hormone is not a consistent inverse rule across all conditions.
• Sample type and measurement method: serum, different plasma preparations, and different assays can produce different results. Some methods also differ in their recognition of intact protein and protein fragments. There is no single precision estimate that applies to every laboratory.
• Study population: associations found in pregnancy, severe obesity, heart failure, cancer, or older adults may not apply to you if your circumstances differ.

Interpreting Changes Over Time

Repeated measurements can document change, but the size of a clinically meaningful change hasn't been established for preventive use. A rise or fall needs to be interpreted alongside changes in your health and other measurements. Having a personal baseline doesn't resolve the uncertainty about what direction is beneficial.